Search

Displaying results 7921 - 7930 of 10000 in total
  1. Drug

    DCVax-L

    go.drugbank.com/drugs/DB17580
    Investigational

    DCVax-L is a personalized immunotherapy comprising an autologous vaccine with dendritic cells loaded _in vitro_ with autologous tumour lysate.

    Synonyms: DCVax-L
  2. Drug

    Ad-CEA vaccine

    go.drugbank.com/drugs/DB17581
    Investigational

    Ad-CEA vaccine is a cancer immunotherapy composed of carcinoembryonic antigen (CEA). … Ad-CEA vaccine is under investigation in clinical trial NCT03050814 (Standard of Care Alone or in Combination With Ad-cea Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal

  3. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    [A257714] While effective, disease progression may occur 6 to 8 months after treatment with currently approved FGFR inhibitors is started, and this effect is usually associated with on-target resistance … KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs).

  4. Drug

    Loxoribine

    go.drugbank.com/drugs/DB17589
    Experimental

    Synonyms: 7-Allyl-7,8-dihydro-8-oxoguanosineCategories: Heterocyclic Compounds, 2-Ring
  5. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients.

  6. Drug

    NP-6A4

    go.drugbank.com/drugs/DB17599
    Experimental

    NP-6A4 is a peptide designed to specifically bind and activate angiotensin II receptor type 2 (AT2R). It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.[A258523]

  7. Drug

    Hemoximer

    go.drugbank.com/drugs/DB17600
    Investigational

    Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering the oxygen affinity, and coupling with polyoxyethylene (POE), to increase its molecular weight.

  8. Drug

    Ixmyelocel-T

    go.drugbank.com/drugs/DB17601
    Investigational

    Ixmyelocel-T is an expanded, autologous multicellular therapy cultured from bone-marrow mononuclear cells. Developed by Vericel Corporation, it is being investigated for cardiomyopathy.

    Synonyms: Ixmyelocel-T
  9. Drug

    CY-1503

    go.drugbank.com/drugs/DB17605
    Investigational

    CY-1503 is a pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-Dglucopyranosyl unit, and one alpha-L-fucopyranosyl

  10. Drug

    CDX-1135

    go.drugbank.com/drugs/DB17607
    Investigational

    CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex).